Our vision and approach
Embedding the patient voice to shape the future of healthcare
Lucid Health Solutions partners with innovators to integrate patient, caregiver, and provider perspectives into every decision that drives outcomes. Founded on the 30+ years of clinical and executive experience of Dr. Anthony Yanni, we scale his life’s work to bring patient-integrated innovation to healthcare organizations across industries and geographies.
“We will celebrate the day when the support we provide is no longer necessary — because every player in healthcare has a strong patient-centric function, are creating solutions with patients that offer meaningful benefit, and they are delivered with the intention to care for the individual and not simply treat an illness.”
- Founder of LHS, Dr. Anthony Yanni
The success behind the programmatic approach to Patient Centricity
Operational: the active integration of the patient perspective in every decision that leads to a patient solution.
Cultural: the conscious awareness of the patient in all activities, for every team member, in every role across all geographies, every day.
For nearly two decades, the leadership of Lucid Health Solutions has been developing and refining processes that improve portfolio decision-making, deepen understanding of patients in real-world settings, and explore the behavioral drivers of health choices. We’ve also helped organizations evolve their cultures to center around the patient—fostering innovation, motivation, and talent retention.
Our programs and those we help you to build are designed to be cost-effective, efficient, and impactful. They reduce waste and redundancies, streamline decision-making, and build institutional knowledge that supports future initiatives. Importantly, these processes are not built for long-term dependency on Lucid. Instead, we empower organizations to become self-sustaining—developing internal expertise, improved decision-making capabilities, refinement of early portfolios while fostering a patient-first culture through active programming.
Team and leadership
Our team of passionate healthcare leaders bring more than 75 years of collective experience across the healthcare value chain, from research & development to human resources & operations and ultimately, clinical care delivery.
-
Dr. Anthony Yanni, a veteran healthcare professional and pharma executive, is Founder and CEO of Lucid Health Solutions. Launched in 2025, Lucid continues Dr. Yanni’s life work - advocating and executing patient centricity in global healthcare practices. As a senior pharma executive at two global companies, Anthony was pivotal in integrating patient perspectives and real-world needs into pharmaceutical innovation, development, and delivery.
A medical practitioner for over a decade, he held crucial roles such as Chief of Internal Medicine and Chief Medical Officer in a Northeastern US health system. His clinical experience led him to recognize the significance of focusing on the patient, not just the disease, resulting in truly meaningful innovations. Anthony’s experience underscores his commitment to integrating patient insights across all functional areas, fostering a patient-centric corporate culture and operating model that extended from early research to product utilization. His leadership is set to revolutionize healthcare, foregrounding the person behind the patient at every stage of medical care.
In 2024, Anthony published his first book, A Bandana and A Bluebird – The Path to a Patient Centric Healthcare System in which he details, through patient vignettes and programmatic examples, the progress made toward achieving a more patient focused system of care as well as the challenges that remain.
Anthony was selected as one of 2021’s 100 Most Inspiring People in the life-sciences industry by PharmaVoice Magazine and was recognized with the 2022 Reuters Pharma Europe Patient Champion Award for having “real impact on patients, carers and international health systems”. In 2024, he was recognized with the Life Sciences Voice Rising Stars Award for “innovative work shaping the future of the life science industry”.
He currently serves on the Board of Trustees of The University of Scranton. Dr. Yanni holds an MD degree from Drexel University/Hahnemann School of Medicine, an MBA from the University of Massachusetts and a BS from the University of Scranton.
-
Over a biopharma career spanning more than 20 years and multiple continents, Tyler has developed a strong track record of establishing and leading high performing teams across life science disciplines including corporate operations, strategy, patient advocacy, communications and investor relations. Until its acquisition by Alumis Inc in May 2025, he was most recently Vice President of Investor Relations and Corporate Operations at ACELYRIN, a clinical stage biotechnology company where he reported to the CEO and was a trusted counselor to the senior leadership team on matters of capital fundraising, enterprise value creation, business development, organizational strategy, and clinical and corporate disclosures.
Tyler previously spent nearly a decade with global pharmaceutical company Astellas in roles of increasing responsibility including Senior Director of Global Strategy and Integration for Patient Centricity, where he reported to Dr. Yanni, Director of Investor Relations and Head of Global Employee Relations, all from the company’s Tokyo headquarters. Earlier in his Astellas career, Tyler was based in Chicago as the Head of Product and Portfolio Communications and served as the company’s first Director of Oncology Communications and Stakeholder Engagement.
An award-winning healthcare leader, in 2016 Tyler was honored by PRWeek as one of the industry’s most influential communicators under the age of 40. Tyler holds an MBA in Finance and Brand Management from Northwestern University's Kellogg School of Management, an MSc in Strategic Communications from Columbia University and a BA in Journalism from Drake University.
-
Keri Oberg Yale is a trailblazer in patient advocacy and a recognized innovator in the pharmaceutical industry. Over her 31-year career at Boehringer Ingelheim Pharmaceuticals Inc., she held numerous leadership roles, most recently serving as Head of Patient Centricity & Engagement. In that role, she led enterprise-wide efforts to embed a patient-centric culture, integrate patient insights across the product lifecycle, and advance the science of patient input to inform research, development, and commercialization strategies.
Her career began with a strong commitment to the HIV/AIDS community, where her vision for collaboration led to the creation of the industry’s first HIV Community Affairs team nearly three decades ago. She later became a founding member of Boehringer’s U.S. patient advocacy relations function and played a key role in establishing its global counterpart. Keri credits HIV advocates for shaping her understanding of authentic patient engagement—long before “patient-focused drug development” became a recognized discipline.
A passionate storyteller and thought leader, she has shared her insights at industry conferences, academic forums, webinars, and podcasts. Today, she continues to help organizations elevate patient engagement, build meaningful partnerships with the patient community, and drive sustainable change across healthcare.
-
Peter M. Loupos is a globally recognized strategist guiding biopharmaceutical industry partners at the intersection of policy and advocacy, medical technology, AI/ML, research, and healthcare delivery. He counsels AI healthcare startups, supports biotech and pharmaceutical companies on complex policy and advocacy initiatives, and brings expert insight to multi-stakeholder biomedical consortia.
With a multidisciplinary background spanning molecular biology, genetics, and computer science, Peter began his career in health IT, leading the development of pioneering healthcare systems across the U.S., Europe, and Japan. He later served as Global Head of R&D IT at Sanofi’s legacy companies, where he drove technology innovations that reshaped the biopharmaceutical R&D model and helped establish industry-wide standards. His collaborations with the FDA on PDUFA negotiations and the agency’s IT strategic plan underscore his role as a trusted partner in regulatory and policy development. Throughout his career, he has built enduring partnerships with advocacy organizations to embed the patient voice in research, while championing access, innovation, and policy reforms to advance global healthcare.
He serves on the Board of the Asthma and Allergy Foundation of America chairing its Strategic Planning Committee, is a member of the Food Allergy Science Initiative Business Advisory Panel and regularly provides guidance to patient advocacy organizations with a particular focus on rare diseases.
-
Loriana Hernández-Aldama is an Emmy award-winning journalist, international speaker, and author of Becoming the Story: The Power of PREhab. A two-time cancer survivor, she brings a unique perspective to healthcare strategy by combining her investigative journalism background with firsthand patient experience navigating complex systems, including AML leukemia, a bone marrow transplant, and breast cancer.
Today, Loriana works with healthcare and life-science organizations to bridge the gap between clinical innovation and real-world patient experience. She helps leaders better understand how trust, communication, and patient perspective influence engagement, adherence, and outcomes.
Known for her bold and transparent approach, she challenges organizations to look beyond data and see the full human story behind each patient journey. She has shared her insights with global audiences across healthcare, research, corporate, and policy sectors, advancing more human-centered care and strategy.